The release of innovative products and the arrival of biosimilars is expected to drive market expansion in the near future at a CAGR of 4.90% during the forecast period 2023 to 2032

Market Research Future (MRFR) has published on the “Global Ankylosing Spondylitis Treatment Market”.

Market Highlights

The global ankylosing spondylitis treatment market is accounted to register a CAGR of 4.90% during the forecast period and is estimated to reach USD 8.1 Billion by 2032.

The ankylosing spondylitis treatment market centers on providing therapies and medications for managing the chronic inflammatory disease affecting the spine and joints. With a focus on improving pain relief, mobility, and overall quality of life for patients, this market drives research and innovation in the field of rheumatology and musculoskeletal disorders.

Key Players

MRFR recognizes the following companies as the key players in the global ankylosing spondylitis treatment market— AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others and others

Segment Analysis

The global ankylosing spondylitis treatment market has been segmented based treatment and end user.

On the basis of treatment, the market is segmented into drugs, physical therapy, surgery and others. The drugs segment dominated the market in 2022. This is due to the increase in ankylosing spondylitis cases and the need for effective treatments for the condition.  

Based on end user, the global ankylosing spondylitis treatment market has been segmented into hospitals, clinics, ambulatory surgery centres and others. The hospitals category generated the most income in 2022. Hospitals are where the majority of ankylosing spondylitis treatments are provided.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Ankylosing Spondylitis Treatment Market Research Report

Regional Analysis

The global ankylosing spondylitis treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe ankylosing spondylitis treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The ankylosing spondylitis treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World ankylosing spondylitis treatment market comprises of Middle East, Africa, and Latin America.

The North America ankylosing spondylitis treatment market dominated this market in 2022 (45.80%). With an estimated 0.5% to 1% of the population suffering from AS, the United States has a notably high prevalence of the condition. This has caused a greater emphasis to be placed on research, diagnosis, and available treatments. The American College of Rheumatology (ACR), for instance, frequently updates its recommendations for the diagnosis and treatment of AS.

Moreover, the Europe market has been persistently growing over the forecast period. Organizations that support sufferers and actively raise awareness of ankylosing spondylitis (AS) include the Ankylosing Spondylitis International Federation (ASIF) in Belgium and the National Ankylosing Spondylitis Society (NASS) in the UK. To enhance patient care, these groups work with legislators and medical experts.

The Asia-Pacific ankylosing spondylitis treatment market is expected to grow at the fastest CAGR from 2023 to 2032. Significant pharmaceutical corporations have increased their presence in the Asia-Pacific area, including Novartis. Cosentyx, a biologic used to treat AS, is marketed by Novartis in nations including China and India. This has boosted access to cutting-edge therapies.

Furthermore, the rest of the world's ankylosing spondylitis treatment market is divided into the Middle East, Africa, and Latin America. The Latin American ankylosing spondylitis treatment market addresses the inflammatory spinal condition with therapies aiming to alleviate pain and enhance mobility. Growing awareness, increasing healthcare access, and collaborations among pharmaceutical firms and healthcare providers contribute to advancing treatment options, bettering patients' quality of life across the region.

Key Findings of the Study

• The global ankylosing spondylitis treatment market is expected to reach USD 8.1 Billion by 2032, at a CAGR of 4.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market. Important pharmaceutical companies, including Novartis, have grown their presence in the Asia-Pacific region. Novartis markets Cosentyx, a biologic used to treat AS, in countries including China and India. Access to innovative treatments has increased as a result.


• Based on treatment, the drugs segment was attributed to holding the largest market in 2022.


• AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others and others.